ArticleFrontiers in pharmacology2025
Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study analyzed neuropsychiatric adverse drug events (ADEs) associated with cetirizine and levocetirizine using data from the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases to inform safer clinical use for different age and gender groups. Methods: We performed disproportionality analyses (ROR, PRR, BCPNN, MGPS) using data from the FAERS (Q1 2004 to Q3 2025) and the EudraVigilance database (January 2002 to December 2025). In addition, stratified analysis was conducted for the top 20 reported ADEs across different sex and age groups. Results: Somnolence, dizziness, headache, and insomnia are common adverse drug reactions (ADRs) with high disproportionality signals for both cetirizine and levocetirizine. Cetirizine was generally associated with higher signal intensities for depression, anxiety, and drug abuse/dependence compared to levocetirizine, with unique reports of cognitive impairment and migraine. In contrast, levocetirizine showed stronger signals not only for sleep-related ADRs but also for serious psychiatric events, including suicide attempts and suicidal ideation. Among levocetirizine users, febrile convulsions were more frequently reported in males. Additionally, pediatric patients exposed to levocetirizine were reported to have febrile convulsion and epilepsy. In the elderly, reports associated with cetirizine included subarachnoid hemorrhage, transient ischemic attack, and carotid artery occlusion, while those for levocetirizine included hepatic encephalopathy. Conclusion: These findings highlight the distinct neuropsychiatric risk profiles associated with cetirizine and levocetirizine. This underscores the importance of age- and sex-informed drug selection to optimize their safe use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.